Skip to content
contact@indiamedicine.orgLogin / Register
IMSDA
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us
Search for:
Menu Close
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us

Blog

  1. Home>
  2. News>
  3. PAXLOVID – CONDITIONS OF USE

PAXLOVID – CONDITIONS OF USE

  • Post published:December 16, 2022
  • Post category:News
paxlovid-pf-07321332-ritonavir-covid-19-article-53-procedure-conditions-use-conditions-distribution_enDownload

MEDICINAL PRODUCT FOR USE

1. Name of the medicinal product for use: PAXLOVID

2. Active substance(s): Nirmatrelvir and ritonavir

3. Pharmaceutical form: Film-coated tablets

4. Route of administration: Oral use

5. Strength: 150 mg Nirmatrelvir , 100 mg ritonavir

Please Share This Share this content

  • Opens in a new window Twitter
  • Opens in a new window Facebook
  • Opens in a new window Google+
  • Opens in a new window Pinterest
  • Opens in a new window LinkedIn
  • Opens in a new window Viber
  • Opens in a new window VK
  • Opens in a new window Reddit
  • Opens in a new window Tumblr
  • Opens in a new window Viadeo
  • Opens in a new window WhatsApp

You Might Also Like

CDSCO Digital Drug Platform: 12 Firms Bid, Rollout Next Month

September 19, 2026

US 100% Pharma Tariff Spares Indian Generics — What Buyers and Exporters Need to Know

May 28, 2026

Latest HIV Treatment Advances and Global Response Challenges (2025)

December 1, 2025

Recent Posts

  • Understanding CDSCO’s NSQ Drug Quality Alerts: A Buyer’s Guide for 2026
    September 30, 2026/
    0 Comments
  • CDSCO’s Risk-Based Regulation Push at iPHEX 2026
    September 29, 2026/
    0 Comments
  • A Buyer’s Guide to WHO-GMP Certified Indian Generic Medicines
    September 28, 2026/
    0 Comments

Follow Us

IMSDA

Recent Posts

  • Understanding CDSCO’s NSQ Drug Quality Alerts: A Buyer’s Guide for 2026
  • CDSCO’s Risk-Based Regulation Push at iPHEX 2026
  • A Buyer’s Guide to WHO-GMP Certified Indian Generic Medicines
  • India’s PLI Bulk Drug Push: Rs 5,210 Crore Invested by June 2026
  • CDSCO’s Digital Drug Regulatory Platform: What Buyers Should Know

Contact Info

  • If you want to touch more medicine sales and distribution resources, you could contact us, or join us.
  • Address:2nd Floor, Bhavani CHS, Dadar West, Mumbai, 400028, Maharashtra.
  • Phone:+91 8048111688
  • Email:contact@indiamedicine.orgOpens in your application
  • Website:https://indiamedicine.org/
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us
© Copyright All Right Reserve